Regulatory T cells in colorectal cancer: From biology to prognostic relevance

Cancers

Volumn 3, Issue 2, 2011, Pages 1708-1731

  Mougiakakos, Dimitrios ^a  

^a Karolinska Krankenhaus   (Sweden)

Author keywords

Colorectal cancer; Immune escape; Prognostic marker; Regulatory T cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARCINOEMBRYONIC ANTIGEN; CD103 ANTIGEN; CD4 ANTIGEN; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 35; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; MACROPHAGE DERIVED CHEMOKINE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CANCER SURGERY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL EXPANSION; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; ENTERITIS; HUMAN; INFLAMMATION; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; OXIDATIVE STRESS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TUMOR IMMUNITY;

EID: 79959726907     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3021708     Document Type: Review

References (143)

1. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148.
2. Kawakami, Y.; Rosenberg, S.A. Human tumor antigens recognized by t-cells. Immunol. Res. 1997, 16, 313-339.
3. Kappler, J.W.; Roehm, N.; Marrack, P. T cell tolerance by clonal elimination in the thymus. Cell 1987, 49, 273-280.
4. Billingham, R.E.; Brent, L.; Medawar, P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172, 603-606.
5. Gershon, R.K.; Kondo, K. Infectious immunological tolerance. Immunology 1971, 21, 903-914.
6. Gershon, R.K.; Kondo, K. Cell interactions in the induction of tolerance: The role of thymic lymphocytes. Immunology 1970, 18, 723-737.
7. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated t cells expressing il-2 receptor alpha-chains (cd25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155, 1151-1164.
8. Baecher-Allan, C.; Brown, J.A.; Freeman, G.J.; Hafler, D.A. Cd4+cd25high regulatory cells in human peripheral blood. J. Immunol. 2001, 167, 1245-1253.
9. Dieckmann, D.; Plottner, H.; Berchtold, S.; Berger, T.; Schuler, G. Ex vivo isolation and characterization of cd4(+)cd25(+) t cells with regulatory properties from human blood. J. Exp. Med. 2001, 193, 1303-1310.
10. Fontenot, J.D.; Gavin, M.A.; Rudensky, A.Y. Foxp3 programs the development and function of cd4+cd25+ regulatory t cells. Nat. Immunol. 2003, 4, 330-336.
11. Roncador, G.; Brown, P.J.; Maestre, L.; Hue, S.; Martinez-Torrecuadrada, J.L.; Ling, K.L.; Pratap, S.; Toms, C.; Fox, B.C.; Cerundolo, V.; Powrie, F.; Banham, A.H. Analysis of foxp3 protein expression in human cd4+cd25+ regulatory t cells at the single-cell level. Eur. J. Immunol. 2005, 35, 1681-1691.
12. Walker, M.R.; Kasprowicz, D.J.; Gersuk, V.H.; Benard, A.; Van Landeghen, M.; Buckner, J.H.; Ziegler, S.F. Induction of foxp3 and acquisition of t regulatory activity by stimulated human cd4+cd25- t cells. J. Clin. Invest. 2003, 112, 1437-1443.
13. Bennett, C.L.; Christie, J.; Ramsdell, F.; Brunkow, M.E.; Ferguson, P.J.; Whitesell, L.; Kelly, T.E.; Saulsbury, F.T.; Chance, P.F.; Ochs, H.D. The immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome (ipex) is caused by mutations of foxp3. Nat. Genet. 2001, 27, 20-21.
14. Brunkow, M.E.; Jeffery, E.W.; Hjerrild, K.A.; Paeper, B.; Clark, L.B.; Yasayko, S.A.; Wilkinson, J.E.; Galas, D.; Ziegler, S.F.; Ramsdell, F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, 27, 68-73.
15. Wing, K.; Sakaguchi, S. Regulatory t cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 2010, 11, 7-13.
16. Valencia, X.; Yarboro, C.; Illei, G.; Lipsky, P.E. Deficient cd4+cd25high t regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007, 178, 2579-2588.
17. Venken, K.; Hellings, N.; Broekmans, T.; Hensen, K.; Rummens, J.L.; Stinissen, P. Natural naive cd4+cd25+cd127low regulatory t cell (treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory treg homeostasis during disease progression. J. Immunol. 2008, 180, 6411-6420.
18. Berendt, M.J.; North, R.J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 1980, 151, 69-80.
19. Fujimoto, S.; Greene, M.I.; Sehon, A.H. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J. Immunol. 1976, 116, 791-799.
20. Fujimoto, S.; Greene, M.I.; Sehon, A.H. Regulation of the immune response to tumor antigens. Ii. The nature of immunosuppressor cells in tumor-bearing hosts. J. Immunol. 1976, 116, 800-806.
21. Sakaguchi, S.; Miyara, M.; Costantino, C.M.; Hafler, D.A. Foxp3+ regulatory t cells in the human immune system. Nat. Rev. Immunol. 2010, 10, 490-500.
22. Woo, E.Y.; Chu, C.S.; Goletz, T.J.; Schlienger, K.; Yeh, H.; Coukos, G.; Rubin, S.C.; Kaiser, L.R.; June, C.H. Regulatory cd4(+)cd25(+) t cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61, 4766-4772.
23. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M.L.; Knutson, K.L.; Chen, L.; Zou, W. Specific recruitment of regulatory t cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949.
24. Jemal, A.; Tiwari, R.C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E.J.; Thun, M.J. Cancer statistics, 2004. CA Cancer J. Clin. 2004, 54, 8-29.
25. Shevach, E.M. From vanilla to 28 flavors: Multiple varieties of t regulatory cells. Immunity 2006, 25, 195-201.
26. Feuerer, M.; Hill, J.A.; Mathis, D.; Benoist, C. Foxp3+ regulatory t cells: Differentiation, specification, subphenotypes. Nat. Immunol. 2009, 10, 689-695.
27. Seddiki, N.; Santner-Nanan, B.; Tangye, S.G.; Alexander, S.I.; Solomon, M.; Lee, S.; Nanan, R.; Fazekas de Saint Groth, B. Persistence of naive cd45ra+ regulatory t cells in adult life. Blood 2006, 107, 2830-2838.
28. Seddiki, N.; Santner-Nanan, B.; Martinson, J.; Zaunders, J.; Sasson, S.; Landay, A.; Solomon, M.; Selby, W.; Alexander, S.I.; Nanan, R.; Kelleher, A.; Fazekas de St Groth, B. Expression of interleukin (il)-2 and il-7 receptors discriminates between human regulatory and activated t cells. J. Exp. Med. 2006, 203, 1693-1700.
29. Liu, W.; Putnam, A.L.; Xu-Yu, Z.; Szot, G.L.; Lee, M.R.; Zhu, S.; Gottlieb, P.A.; Kapranov, P.; Gingeras, T.R.; Fazekas de St Groth, B.; Clayberger, C.; Soper, D.M.; Ziegler, S.F.; Bluestone, J.A. Cd127 expression inversely correlates with foxp3 and suppressive function of human cd4+ t reg cells. J. Exp. Med. 2006, 203, 1701-1711.
30. Groux, H.; O'Garra, A.; Bigler, M.; Rouleau, M.; Antonenko, S.; de Vries, J.E.; Roncarolo, M.G. A cd4+ t-cell subset inhibits antigen-specific t-cell responses and prevents colitis. Nature 1997, 389, 737-742.
31. Vieira, P.L.; Christensen, J.R.; Minaee, S.; O'Neill, E.J.; Barrat, F.J.; Boonstra, A.; Barthlott, T.; Stockinger, B.; Wraith, D.C.; O'Garra, A. Il-10-secreting regulatory t cells do not express foxp3 but have comparable regulatory function to naturally occurring cd4+cd25+ regulatory t cells. J. Immunol. 2004, 172, 5986-5993.
32. Mougiakakos, D.; Choudhury, A.; Lladser, A.; Kiessling, R.; Johansson, C.C. Regulatory t cells in cancer. Adv. Cancer. Res. 2010, 107, 57-117.
33. Chen, W.; Jin, W.; Hardegen, N.; Lei, K.J.; Li, L.; Marinos, N.; McGrady, G.; Wahl, S.M. Conversion of peripheral cd4+cd25- naive t cells to cd4+cd25+ regulatory t cells by tgf-beta induction of transcription factor foxp3. J. Exp. Med. 2003, 198, 1875-1886.
34. Apostolou, I.; von Boehmer, H. In vivo instruction of suppressor commitment in naive t cells. J. Exp. Med. 2004, 199, 1401-1408.
35. Wong, J.; Obst, R.; Correia-Neves, M.; Losyev, G.; Mathis, D.; Benoist, C. Adaptation of tcr repertoires to self-peptides in regulatory and nonregulatory cd4+ t cells. J. Immunol. 2007, 178, 7032-7041.
36. Wei, S.; Kryczek, I.; Zou, L.; Daniel, B.; Cheng, P.; Mottram, P.; Curiel, T.; Lange, A.; Zou, W. Plasmacytoid dendritic cells induce cd8+ regulatory t cells in human ovarian carcinoma. Cancer Res. 2005, 65, 5020-5026.
37. Hoechst, B.; Ormandy, L.A.; Ballmaier, M.; Lehner, F.; Kruger, C.; Manns, M.P.; Greten, T.F.; Korangy, F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces cd4(+)cd25(+)foxp3(+) t cells. Gastroenterology 2008, 135, 234-243.
38. Hahn, B.H.; Singh, R.P.; La Cava, A.; Ebling, F.M. Tolerogenic treatment of lupus mice with consensus peptide induces foxp3-expressing, apoptosis-resistant, tgfbeta-secreting cd8+ t cell suppressors. J. Immunol. 2005, 175, 7728-7737.
39. Filaci, G.; Fenoglio, D.; Fravega, M.; Ansaldo, G.; Borgonovo, G.; Traverso, P.; Villaggio, B.; Ferrera, A.; Kunkl, A.; Rizzi, M.; Ferrera, F.; Balestra, P.; Ghio, M.; Contini, P.; Setti, M.; Olive, D.; Azzarone, B.; Carmignani, G.; Ravetti, J.L.; Torre, G.; Indiveri, F. Cd8+ cd28- t regulatory lymphocytes inhibiting t cell proliferative and cytotoxic functions infiltrate human cancers. J. Immunol. 2007, 179, 4323-4334.
40. Kiniwa, Y.; Miyahara, Y.; Wang, H.Y.; Peng, W.; Peng, G.; Wheeler, T.M.; Thompson, T.C.; Old, L.J.; Wang, R.F. Cd8+ foxp3+ regulatory t cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 2007, 13, 6947-6958.
41. Fischer, K.; Voelkl, S.; Heymann, J.; Przybylski, G.K.; Mondal, K.; Laumer, M.; Kunz-Schughart, L.; Schmidt, C.A.; Andreesen, R.; Mackensen, A. Isolation and characterization of human antigen-specific tcr alpha beta+ cd4(-)cd8- double-negative regulatory t cells. Blood 2005, 105, 2828-2835.
42. Peng, G.; Wang, H.Y.; Peng, W.; Kiniwa, Y.; Seo, K.H.; Wang, R.F. Tumor-infiltrating gammadelta t cells suppress t and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007, 27, 334-348.
43. Tran, D.Q.; Glass, D.D.; Uzel, G.; Darnell, D.A.; Spalding, C.; Holland, S.M.; Shevach, E.M. Analysis of adhesion molecules, target cells, and role of il-2 in human foxp3+ regulatory t cell suppressor function. J. Immunol. 2009, 182, 2929-2938.
44. Strauss, L.; Bergmann, C.; Szczepanski, M.; Gooding, W.; Johnson, J.T.; Whiteside, T.L. A unique subset of cd4+cd25highfoxp3+ t cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007, 13, 4345-4354.
45. Kuhn, R.; Lohler, J.; Rennick, D.; Rajewsky, K.; Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75, 263-274.
46. Kulkarni, A.B.; Huh, C.G.; Becker, D.; Geiser, A.; Lyght, M.; Flanders, K.C.; Roberts, A.B.; Sporn, M.B.; Ward, J.M.; Karlsson, S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 1993, 90, 770-774.
47. Ghiringhelli, F.; Menard, C.; Terme, M.; Flament, C.; Taieb, J.; Chaput, N.; Puig, P.E.; Novault, S.; Escudier, B.; Vivier, E.; Lecesne, A.; Robert, C.; Blay, J.Y.; Bernard, J.; Caillat-Zucman, S.; Freitas, A.; Tursz, T.; Wagner-Ballon, O.; Capron, C.; Vainchencker, W.; Martin, F.; Zitvogel, L. Cd4+cd25+ regulatory t cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005, 202, 1075-1085.
48. Yaqub, S.; Henjum, K.; Mahic, M.; Jahnsen, F.L.; Aandahl, E.M.; Bjornbeth, B.A.; Tasken, K. Regulatory t cells in colorectal cancer patients suppress anti-tumor immune activity in a cox-2 dependent manner. Cancer Immunol. Immunother. 2008, 57, 813-821.
49. Mandapathil, M.; Szczepanski, M.J.; Szajnik, M.; Ren, J.; Jackson, E.K.; Johnson, J.T.; Gorelik, E.; Lang, S.; Whiteside, T.L. Adenosine and prostaglandin e2 cooperate in the suppression of immune responses mediated by adaptive regulatory t cells. J. Biol. Chem. 2010, 285, 27571-27580.
50. Collison, L.W.; Workman, C.J.; Kuo, T.T.; Boyd, K.; Wang, Y.; Vignali, K.M.; Cross, R.; Sehy, D.; Blumberg, R.S.; Vignali, D.A. The inhibitory cytokine il-35 contributes to regulatory t-cell function. Nature 2007, 450, 566-569.
51. Collison, L.W.; Chaturvedi, V.; Henderson, A.L.; Giacomin, P.R.; Guy, C.; Bankoti, J.; Finkelstein, D.; Forbes, K.; Workman, C.J.; Brown, S.A.; Rehg, J.E.; Jones, M.L.; Ni, H.T.; Artis, D.; Turk, M.J.; Vignali, D.A. Il-35-mediated induction of a potent regulatory t cell population. Nat. Immunol. 2010, 11, 1093-1101.
52. Bardel, E.; Larousserie, F.; Charlot-Rabiega, P.; Coulomb-L'Hermine, A.; Devergne, O. Human cd4+ cd25+ foxp3+ regulatory t cells do not constitutively express il-35. J. Immunol. 2008, 181, 6898-6905.
53. Cao, X.; Cai, S.F.; Fehniger, T.A.; Song, J.; Collins, L.I.; Piwnica-Worms, D.R.; Ley, T.J. Granzyme b and perforin are important for regulatory t cell-mediated suppression of tumor clearance. Immunity 2007, 27, 635-646.
54. Ren, X.; Ye, F.; Jiang, Z.; Chu, Y.; Xiong, S.; Wang, Y. Involvement of cellular death in trail/dr5-dependent suppression induced by cd4(+)cd25(+) regulatory t cells. Cell Death Differ. 2007, 14, 2076-2084.
55. Toscano, M.A.; Bianco, G.A.; Ilarregui, J.M.; Croci, D.O.; Correale, J.; Hernandez, J.D.; Zwirner, N.W.; Poirier, F.; Riley, E.M.; Baum, L.G.; Rabinovich, G.A. Differential glycosylation of th1, th2 and th-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 2007, 8, 825-834.
56. Tadokoro, C.E.; Shakhar, G.; Shen, S.; Ding, Y.; Lino, A.C.; Maraver, A.; Lafaille, J.J.; Dustin, M.L. Regulatory t cells inhibit stable contacts between cd4+ t cells and dendritic cells in vivo. J. Exp. Med. 2006, 203, 505-511.
57. Read, S.; Malmstrom, V.; Powrie, F. Cytotoxic t lymphocyte-associated antigen 4 plays an essential role in the function of cd25(+)cd4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 2000, 192, 295-302.
58. Mellor, A.L.; Munn, D.H. Ido expression by dendritic cells: Tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4, 762-774.
59. Huang, C.T.; Workman, C.J.; Flies, D.; Pan, X.; Marson, A.L.; Zhou, G.; Hipkiss, E.L.; Ravi, S.; Kowalski, J.; Levitsky, H.I.; Powell, J.D.; Pardoll, D.M.; Drake, C.G.; Vignali, D.A. Role of lag-3 in regulatory t cells. Immunity 2004, 21, 503-513.
60. Sarris, M.; Andersen, K.G.; Randow, F.; Mayr, L.; Betz, A.G. Neuropilin-1 expression on regulatory t cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008, 28, 402-413.
61. Wilhelm, K.; Ganesan, J.; Muller, T.; Durr, C.; Grimm, M.; Beilhack, A.; Krempl, C.D.; Sorichter, S.; Gerlach, U.V.; Juttner, E.; Zerweck, A.; Gartner, F.; Pellegatti, P.; Di Virgilio, F.; Ferrari, D.; Kambham, N.; Fisch, P.; Finke, J.; Idzko, M.; Zeiser, R. Graft-versus-host disease is enhanced by extracellular atp activating p2x(7)r. Nat. Med. 2010, 16, 1434-1438.
62. Deaglio, S.; Dwyer, K.M.; Gao, W.; Friedman, D.; Usheva, A.; Erat, A.; Chen, J.F.; Enjyoji, K.; Linden, J.; Oukka, M.; Kuchroo, V.K.; Strom, T.B.; Robson, S.C. Adenosine generation catalyzed by cd39 and cd73 expressed on regulatory t cells mediates immune suppression. J. Exp. Med. 2007, 204, 1257-1265.
63. Wilson, J.M.; Ross, W.G.; Agbai, O.N.; Frazier, R.; Figler, R.A.; Rieger, J.; Linden, J.; Ernst, P.B. The a2b adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J. Immunol. 2009, 182, 4616-4623.
64. Bopp, T.; Becker, C.; Klein, M.; Klein-Hessling, S.; Palmetshofer, A.; Serfling, E.; Heib, V.; Becker, M.; Kubach, J.; Schmitt, S.; Stoll, S.; Schild, H.; Staege, M.S.; Stassen, M.; Jonuleit, H.; Schmitt, E. Cyclic adenosine monophosphate is a key component of regulatory t cell-mediated suppression. J. Exp. Med. 2007, 204, 1303-1310.
65. Pandiyan, P.; Zheng, L.; Ishihara, S.; Reed, J.; Lenardo, M.J. Cd4+cd25+foxp3+ regulatory t cells induce cytokine deprivation-mediated apoptosis of effector cd4+ t cells. Nat. Immunol. 2007, 8, 1353-1362.
66. Tran, D.Q.; Andersson, J.; Hardwick, D.; Bebris, L.; Illei, G.G.; Shevach, E.M. Selective expression of latency-associated peptide (lap) and il-1 receptor type i/ii (cd121a/cd121b) on activated human foxp3+ regulatory t cells allows for their purification from expansion cultures. Blood 2009, 113, 5125-5133.
67. Yan, Z.; Garg, S.K.; Kipnis, J.; Banerjee, R. Extracellular redox modulation by regulatory t cells. Nat. Chem. Biol. 2009, 5, 721-723.
68. Yan, Z.; Garg, S.K.; Banerjee, R. Regulatory t cells interfere with glutathione metabolism in dendritic cells and t cells. J. Biol. Chem. 2010.
69. Mougiakakos, D.; Johansson, C.C.; Kiessling, R. Naturally occurring regulatory t cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 2009, 113, 3542-3545.
70. Mougiakakos, D.; Johansson, C.C.; Jitschin, R.; Bottcher, M.; Kiessling, R. Increased thioredoxin-1 production in human naturally occurring regulatory t cells confers enhanced tolerance to oxidative stress. Blood 2010, 117, 857-861.
71. Jordan, J.T.; Sun, W.; Hussain, S.F.; DeAngulo, G.; Prabhu, S.S.; Heimberger, A.B. Preferential migration of regulatory t cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother. 2008, 57, 123-131.
72. Tan, M.C.; Goedegebuure, P.S.; Belt, B.A.; Flaherty, B.; Sankpal, N.; Gillanders, W.E.; Eberlein, T.J.; Hsieh, C.S.; Linehan, D.C. Disruption of ccr5-dependent homing of regulatory t cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 2009, 182, 1746-1755.
73. Mizukami, Y.; Kono, K.; Kawaguchi, Y.; Akaike, H.; Kamimura, K.; Sugai, H.; Fujii, H. Ccl17 and ccl22 chemokines within tumor microenvironment are related to accumulation of foxp3+ regulatory t cells in gastric cancer. Int. J. Cancer 2008, 122, 2286-2293.
74. Gobert, M.; Treilleux, I.; Bendriss-Vermare, N.; Bachelot, T.; Goddard-Leon, S.; Arfi, V.; Biota, C.; Doffin, A.C.; Durand, I.; Olive, D.; Perez, S.; Pasqual, N.; Faure, C.; Ray-Coquard, I.; Puisieux, A.; Caux, C.; Blay, J.Y.; Menetrier-Caux, C. Regulatory t cells recruited through ccl22/ccr4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69, 2000-2009.
75. Wolf, D.; Rumpold, H.; Koppelstatter, C.; Gastl, G.A.; Steurer, M.; Mayer, G.; Gunsilius, E.; Tilg, H.; Wolf, A.M. Telomere length of in vivo expanded cd4(+)cd25 (+) regulatory t-cells is preserved in cancer patients. Cancer Immunol. Immunother. 2006, 55, 1198-1208.
76. Ghiringhelli, F.; Puig, P.E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B.; Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into tgf-beta-secreting cells inducing cd4+cd25+ regulatory t cell proliferation. J. Exp. Med. 2005, 202, 919-929.
77. Lal, G.; Bromberg, J.S. Epigenetic mechanisms of regulation of foxp3 expression. Blood 2009, 114, 3727-3735.
78. Yamagiwa, S.; Gray, J.D.; Hashimoto, S.; Horwitz, D.A. A role for TGF-beta in the generation and expansion of cd4+cd25+ regulatory t cells from human peripheral blood. J. Immunol. 2001, 166, 7282-7289.
79. Bergmann, C.; Strauss, L.; Wang, Y.; Szczepanski, M.J.; Lang, S.; Johnson, J.T.; Whiteside, T.L. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 2008, 14, 3706-3715.
80. Gray, C.P.; Arosio, P.; Hersey, P. Association of increased levels of heavy-chain ferritin with increased cd4+ cd25+ regulatory t-cell levels in patients with melanoma. Clin. Cancer Res. 2003, 9, 2551-2559.
81. Bergmann, C.; Strauss, L.; Zeidler, R.; Lang, S.; Whiteside, T.L. Expansion of human t regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 2007, 67, 8865-8873.
82. El Andaloussi, A.; Lesniak, M.S. Cd4+ cd25+ foxp3+ t-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J. Neurooncol. 2007, 83, 145-152.
83. Pages, F.; Berger, A.; Camus, M.; Sanchez-Cabo, F.; Costes, A.; Molidor, R.; Mlecnik, B.; Kirilovsky, A.; Nilsson, M.; Damotte, D.; Meatchi, T.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H.; Galon, J. Effector memory t cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353, 2654-2666.
84. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval, P.; Cugnenc, P.H.; Trajanoski, Z.; Fridman, W.H.; Pages, F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
85. Zisman, T.L.; Rubin, D.T. Colorectal cancer and dysplasia in inflammatory bowel disease. World J. Gastroenterol. 2008, 14, 2662-2669.
86. Smalley, W.E.; DuBois, R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 1997, 39, 1-20.
87. Bromberg, J.; Wang, T.C. Inflammation and cancer: Il-6 and stat3 complete the link. Cancer Cell 2009, 15, 79-80.
88. Belkaid, Y.; Rouse, B.T. Natural regulatory t cells in infectious disease. Nat. Immunol. 2005, 6, 353-360.
89. Sather, B.D.; Treuting, P.; Perdue, N.; Miazgowicz, M.; Fontenot, J.D.; Rudensky, A.Y.; Campbell, D.J. Altering the distribution of foxp3(+) regulatory t cells results in tissue-specific inflammatory disease. J. Exp. Med. 2007, 204, 1335-1347.
90. Makita, S.; Kanai, T.; Oshima, S.; Uraushihara, K.; Totsuka, T.; Sawada, T.; Nakamura, T.; Koganei, K.; Fukushima, T.; Watanabe, M. Cd4+cd25bright t cells in human intestinal lamina propria as regulatory cells. J. Immunol. 2004, 173, 3119-3130.
91. Holmen, N.; Lundgren, A.; Lundin, S.; Bergin, A.M.; Rudin, A.; Sjovall, H.; Ohman, L. Functional cd4+cd25high regulatory t cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm. Bowel Dis. 2006, 12, 447-456.
92. Anz, D.; Mueller, W.; Golic, M.; Kunz, W.G.; Rapp, M.; Koelzer, V.H.; Ellermeier, J.; Ellwart, J.W.; Schnurr, M.; Bourquin, C.; Endres, S. Cd103 is a hallmark of tumor-infiltrating regulatory t cells. Int. J. Cancer. 2011, DOI: 10.1002/ijc.25902.
93. Erdman, S.E.; Poutahidis, T. Roles for inflammation and regulatory t cells in colon cancer. Toxicol. Pathol. 2010, 38, 76-87.
94. Boivin, G.P.; Washington, K.; Yang, K.; Ward, J.M.; Pretlow, T.P.; Russell, R.; Besselsen, D.G.; Godfrey, V.L.; Doetschman, T.; Dove, W.F.; Pitot, H.C.; Halberg, R.B.; Itzkowitz, S.H.; Groden, J.; Coffey, R.J. Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology 2003, 124, 762-777.
95. Morin, P.J.; Sparks, A.B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K.W. Activation of beta-catenin-tcf signaling in colon cancer by mutations in beta-catenin or apc. Science 1997, 275, 1787-1790.
96. Erdman, S.E.; Sohn, J.J.; Rao, V.P.; Nambiar, P.R.; Ge, Z.; Fox, J.G.; Schauer, D.B. Cd4+cd25+ regulatory lymphocytes induce regression of intestinal tumors in apcmin/+ mice. Cancer Res. 2005, 65, 3998-4004.
97. Poutahidis, T.; Haigis, K.M.; Rao, V.P.; Nambiar, P.R.; Taylor, C.L.; Ge, Z.; Watanabe, K.; Davidson, A.; Horwitz, B.H.; Fox, J.G.; Erdman, S.E. Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis 2007, 28, 2614-2623.
98. Erdman, S.E.; Rao, V.P.; Olipitz, W.; Taylor, C.L.; Jackson, E.A.; Levkovich, T.; Lee, C.W.; Horwitz, B.H.; Fox, J.G.; Ge, Z.; Poutahidis, T. Unifying roles for regulatory t cells and inflammation in cancer. Int. J. Cancer 2010, 126, 1651-1665.
99. Erdman, S.E.; Poutahidis, T. Cancer inflammation and regulatory t cells. Int. J. Cancer 2010, 127, 768-779.
100. Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T.B.; Oukka, M.; Weiner, H.L.; Kuchroo, V.K. Reciprocal developmental pathways for the generation of pathogenic effector th17 and regulatory t cells. Nature 2006, 441, 235-238.
101. Yang, X.O.; Nurieva, R.; Martinez, G.J.; Kang, H.S.; Chung, Y.; Pappu, B.P.; Shah, B.; Chang, S.H.; Schluns, K.S.; Watowich, S.S.; Feng, X.H.; Jetten, A.M.; Dong, C. Molecular antagonism and plasticity of regulatory and inflammatory t cell programs. Immunity 2008, 29, 44-56.
102. Ziegler, S.F.; Buckner, J.H. Foxp3 and the regulation of treg/th17 differentiation. Microbes. Infect. 2009, 11, 594-598.
103. Powrie, F.; Maloy, K.J. Immunology. Regulating the regulators. Science 2003, 299, 1030-1031.
104. Gounaris, E.; Blatner, N.R.; Dennis, K.; Magnusson, F.; Gurish, M.F.; Strom, T.B.; Beckhove, P.; Gounari, F.; Khazaie, K. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 2009, 69, 5490-5497.
105. Blatner, N.R.; Bonertz, A.; Beckhove, P.; Cheon, E.C.; Krantz, S.B.; Strouch, M.; Weitz, J.; Koch, M.; Halverson, A.L.; Bentrem, D.J.; Khazaie, K. In colorectal cancer mast cells contribute to systemic regulatory t-cell dysfunction. Proc. Natl. Acad. Sci. USA 2010, 107, 6430-6435.
106. Somasundaram, R.; Jacob, L.; Swoboda, R.; Caputo, L.; Song, H.; Basak, S.; Monos, D.; Peritt, D.; Marincola, F.; Cai, D.; Birebent, B.; Bloome, E.; Kim, J.; Berencsi, K.; Mastrangelo, M.; Herlyn, D. Inhibition of cytolytic t lymphocyte proliferation by autologous cd4+/cd25+ regulatory t cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002, 62, 5267-5272.
107. Wolf, A.M.; Wolf, D.; Steurer, M.; Gastl, G.; Gunsilius, E.; Grubeck-Loebenstein, B. Increase of regulatory t cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003, 9, 606-612.
108. Ling, K.L.; Pratap, S.E.; Bates, G.J.; Singh, B.; Mortensen, N.J.; George, B.D.; Warren, B.F.; Piris, J.; Roncador, G.; Fox, S.B.; Banham, A.H.; Cerundolo, V. Increased frequency of regulatory t cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 2007, 7, 7.
109. Correale, P.; Cusi, M.G.; Tsang, K.Y.; Del Vecchio, M.T.; Marsili, S.; Placa, M.L.; Intrivici, C.; Aquino, A.; Micheli, L.; Nencini, C.; Ferrari, F.; Giorgi, G.; Bonmassar, E.; Francini, G. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus folfox 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J. Clin. Oncol. 2005, 23, 8950-8958.
110. Clarke, S.L.; Betts, G.J.; Plant, A.; Wright, K.L.; El-Shanawany, T.M.; Harrop, R.; Torkington, J.; Rees, B.I.; Williams, G.T.; Gallimore, A.M.; Godkin, A.J. Cd4+cd25+foxp3+ regulatory t cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006, 1, e129.
111. Chaput, N.; Louafi, S.; Bardier, A.; Charlotte, F.; Vaillant, J.C.; Menegaux, F.; Rosenzwajg, M.; Lemoine, F.; Klatzmann, D.; Taieb, J. Identification of cd8+cd25+foxp3+ suppressive t cells in colorectal cancer tissue. Gut 2009, 58, 520-529.
112. Loddenkemper, C.; Schernus, M.; Noutsias, M.; Stein, H.; Thiel, E.; Nagorsen, D. In situ analysis of foxp3+ regulatory t cells in human colorectal cancer. J. Transl. Med. 2006, 4, 52.
113. Nagorsen, D.; Voigt, S.; Berg, E.; Stein, H.; Thiel, E.; Loddenkemper, C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: Relation to local regulatory t cells, systemic t-cell response against tumor-associated antigens and survival. J. Transl. Med. 2007, 5, 62.
114. Bonertz, A.; Weitz, J.; Pietsch, D.H.; Rahbari, N.N.; Schlude, C.; Ge, Y.; Juenger, S.; Vlodavsky, I.; Khazaie, K.; Jaeger, D.; Reissfelder, C.; Antolovic, D.; Aigner, M.; Koch, M.; Beckhove, P. Antigen-specific tregs control t cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 2009, 119, 3311-3321.
115. Bueter, M.; Gasser, M.; Schramm, N.; Lebedeva, T.; Tocco, G.; Gerstlauer, C.; Grimm, M.; Nichiporuk, E.; Thalheimer, A.; Thiede, A.; Meyer, D.; Benichou, G.; Waaga-Gasser, A.M. T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma. Int. J. Oncol. 2006, 28, 431-438.
116. Yang, S.; Wang, B.; Guan, C.; Wu, B.; Cai, C.; Wang, M.; Zhang, B.; Liu, T.; Yang, P. Foxp3+il-17+ t cells promote development of cancer-initiating cells in colorectal cancer. J. Leukoc. Biol. 2011, 89, 85-91.
117. Gryfe, R.; Kim, H.; Hsieh, E.T.; Aronson, M.D.; Holowaty, E.J.; Bull, S.B.; Redston, M.; Gallinger, S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 2000, 342, 69-77.
118. Michel, S.; Benner, A.; Tariverdian, M.; Wentzensen, N.; Hoefler, P.; Pommerencke, T.; Grabe, N.; von Knebel Doeberitz, M.; Kloor, M. High density of foxp3-positive t cells infiltrating colorectal cancers with microsatellite instability. Br. J. Cancer 2008, 99, 1867-1873.
119. Sinicrope, F.A.; Rego, R.L.; Ansell, S.M.; Knutson, K.L.; Foster, N.R.; Sargent, D.J. Intraepithelial effector (cd3+)/regulatory (foxp3+) t-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137, 1270-1279.
120. Nosho, K.; Baba, Y.; Tanaka, N.; Shima, K.; Hayashi, M.; Meyerhardt, J.A.; Giovannucci, E.; Dranoff, G.; Fuchs, C.S.; Ogino, S. Tumour-infiltrating t-cell subsets, molecular changes in colorectal cancer, and prognosis: Cohort study and literature review. J. Pathol. 2010, 222, 350-366.
121. Le Gouvello, S.; Bastuji-Garin, S.; Aloulou, N.; Mansour, H.; Chaumette, M.T.; Berrehar, F.; Seikour, A.; Charachon, A.; Karoui, M.; Leroy, K.; Farcet, J.P.; Sobhani, I. High prevalence of foxp3 and il17 in mmr-proficient colorectal carcinomas. Gut 2008, 57, 772-779.
122. Pillai, V.; Karandikar, N.J. Attack on the clones? Human foxp3 detection by pch101, 236a/e7, 206d, and 259d reveals 259d as the outlier with lower sensitivity. Blood 2008, 111, 463-464; author reply 464-466.
123. Woo, Y.L.; Sterling, J.; Crawford, R.; van der Burg, S.H.; Coleman, N.; Stanley, M. Foxp3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: Poor correlation between different antibodies. J. Clin. Pathol. 2008, 61, 969-971.
124. Salama, P.; Phillips, M.; Grieu, F.; Morris, M.; Zeps, N.; Joseph, D.; Platell, C.; Iacopetta, B. Tumor-infiltrating foxp3+ t regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009, 27, 186-192.
125. Erdman, S.E.; Rao, V.P.; Poutahidis, T.; Ihrig, M.M.; Ge, Z.; Feng, Y.; Tomczak, M.; Rogers, A.B.; Horwitz, B.H.; Fox, J.G. Cd4(+)cd25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 2003, 63, 6042-6050.
126. Frey, D.M.; Droeser, R.A.; Viehl, C.T.; Zlobec, I.; Lugli, A.; Zingg, U.; Oertli, D.; Kettelhack, C.; Terracciano, L.; Tornillo, L. High frequency of tumor-infiltrating foxp3(+) regulatory t cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 2010, 126, 2635-2643.
127. Correale, P.; Rotundo, M.S.; Del Vecchio, M.T.; Remondo, C.; Migali, C.; Ginanneschi, C.; Tsang, K.Y.; Licchetta, A.; Mannucci, S.; Loiacono, L.; Tassone, P.; Francini, G.; Tagliaferri, P. Regulatory (foxp3+) t-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 2010, 33, 435-441.
128. Suzuki, H.; Chikazawa, N.; Tasaka, T.; Wada, J.; Yamasaki, A.; Kitaura, Y.; Sozaki, M.; Tanaka, M.; Onishi, H.; Morisaki, T.; Katano, M. Intratumoral cd8(+) t/foxp3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol. Immunother. 2010, 59, 653-661.
129. Deng, L.; Zhang, H.; Luan, Y.; Zhang, J.; Xing, Q.; Dong, S.; Wu, X.; Liu, M.; Wang, S. Accumulation of foxp3+ t regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin. Cancer Res. 2010, 16, 4105-4112.
130. Matera, L.; Sandrucci, S.; Mussa, A.; Boffa, C.; Castellano, I.; Cassoni, P. Low foxp3 expression in negative sentinel lymph nodes is associated with node metastases in colorectal cancer. Gut 2010, 59, 419-420.
131. Saha, A.; Chatterjee, S.K. Combination of ctl-associated antigen-4 blockade and depletion of cd25 regulatory t cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand. J. Immunol. 2010, 71, 70-82.
132. Colombo, M.P.; Piconese, S. Regulatory-t-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat. Rev. Cancer 2007, 7, 880-887.
133. Ghiringhelli, F.; Menard, C.; Puig, P.E.; Ladoire, S.; Roux, S.; Martin, F.; Solary, E.; Le Cesne, A.; Zitvogel, L.; Chauffert, B. Metronomic cyclophosphamide regimen selectively depletes cd4+cd25+ regulatory t cells and restores t and nk effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56, 641-648.
134. Audia, S.; Nicolas, A.; Cathelin, D.; Larmonier, N.; Ferrand, C.; Foucher, P.; Fanton, A.; Bergoin, E.; Maynadie, M.; Arnould, L.; Bateman, A.; Lorcerie, B.; Solary, E.; Chauffert, B.; Bonnotte, B. Increase of cd4+ cd25+ regulatory t cells in the peripheral blood of patients with metastatic carcinoma: A phase i clinical trial using cyclophosphamide and immunotherapy to eliminate cd4+ cd25+ t lymphocytes. Clin. Exp. Immunol. 2007, 150, 523-530.
135. Dannull, J.; Su, Z.; Rizzieri, D.; Yang, B.K.; Coleman, D.; Yancey, D.; Zhang, A.; Dahm, P.; Chao, N.; Gilboa, E.; Vieweg, J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory t cells. J. Clin. Invest. 2005, 115, 3623-3633.
136. Morse, M.A.; Hobeika, A.C.; Osada, T.; Serra, D.; Niedzwiecki, D.; Lyerly, H.K.; Clay, T.M. Depletion of human regulatory t cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112, 610-618.
137. Okita, R.; Yamaguchi, Y.; Ohara, M.; Hironaka, K.; Okawaki, M.; Nagamine, I.; Ikeda, T.; Emi, A.; Hihara, J.; Okada, M. Targeting of cd4+cd25high cells while preserving cd4+cd25low cells with low-dose chimeric anti-cd25 antibody in adoptive immunotherapy of cancer. Int. J. Oncol. 2009, 34, 563-572.
138. Rech, A.J.; Vonderheide, R.H. Clinical use of anti-cd25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory t cells. Ann. N. Y. Acad. Sci. 2009, 1174, 99-106.
139. Egen, J.G.; Kuhns, M.S.; Allison, J.P. Ctla-4: New insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002, 3, 611-618.
140. Takahashi, T.; Tagami, T.; Yamazaki, S.; Uede, T.; Shimizu, J.; Sakaguchi, N.; Mak, T.W.; Sakaguchi, S. Immunologic self-tolerance maintained by cd25(+)cd4(+) regulatory t cells constitutively expressing cytotoxic t lymphocyte-associated antigen 4. J. Exp. Med. 2000, 192, 303-310.
141. Liakou, C.I.; Kamat, A.; Tang, D.N.; Chen, H.; Sun, J.; Troncoso, P.; Logothetis, C.; Sharma, P. Ctla-4 blockade increases ifngamma-producing cd4+icoshi cells to shift the ratio of effector to regulatory t cells in cancer patients. Proc. Natl. Acad. Sci. USA 2008, 105, 14987-14992.
142. Yuan, J.; Gnjatic, S.; Li, H.; Powel, S.; Gallardo, H.F.; Ritter, E.; Ku, G.Y.; Jungbluth, A.A.; Segal, N.H.; Rasalan, T.S.; Manukian, G.; Xu, Y.; Roman, R.A.; Terzulli, S.L.; Heywood, M.; Pogoriler, E.; Ritter, G.; Old, L.J.; Allison, J.P.; Wolchok, J.D. Ctla-4 blockade enhances polyfunctional ny-eso-1 specific t cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 2008, 105, 20410-20415.
143. Nyirenda, M.H.; O'Brien, K.; Sanvito, L.; Constantinescu, C.S.; Gran, B. Modulation of regulatory t cells in health and disease: Role of toll-like receptors. Inflamm. Allergy Drug Targets 2009, 8, 124-129.